Table 3 Best overall response.

From: Safety and preliminary immunogenicity of JNJ-64041809, a live-attenuated, double-deleted Listeria monocytogenes-based immunotherapy, in metastatic castration-resistant prostate cancer

Best overall response, n (%)

1 × 108 CFU n = 6

1 × 109 CFU n = 19

Total n = 25a

Stable disease

3 (50)

10 (53)

13 (52)

Progressive disease

2 (33)

7 (37)

9 (36)

Non-evaluableb

1 (17)

2 (11)

3 (12)

  1. aOnly 25 patients had measurable disease at baseline and were evaluable for response per RECIST.
  2. bThree patients were not evaluable by RECIST due to the absence of radiographic progression.
  3. CFU colony-forming unit.
Back to article page